ATE74510T1 - Adoptivimmuntherapie als behandlungsmodalitaet bei menschen. - Google Patents

Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.

Info

Publication number
ATE74510T1
ATE74510T1 AT86401770T AT86401770T ATE74510T1 AT E74510 T1 ATE74510 T1 AT E74510T1 AT 86401770 T AT86401770 T AT 86401770T AT 86401770 T AT86401770 T AT 86401770T AT E74510 T1 ATE74510 T1 AT E74510T1
Authority
AT
Austria
Prior art keywords
cells
lak
cancer
patients
leukaphereses
Prior art date
Application number
AT86401770T
Other languages
English (en)
Inventor
Steven A Rosenbert
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE74510T1 publication Critical patent/ATE74510T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT86401770T 1985-08-08 1986-08-07 Adoptivimmuntherapie als behandlungsmodalitaet bei menschen. ATE74510T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/763,657 US4690915A (en) 1985-08-08 1985-08-08 Adoptive immunotherapy as a treatment modality in humans
EP86401770A EP0211769B1 (de) 1985-08-08 1986-08-07 Adoptivimmuntherapie als Behandlungsmodalität bei Menschen

Publications (1)

Publication Number Publication Date
ATE74510T1 true ATE74510T1 (de) 1992-04-15

Family

ID=25068444

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86401770T ATE74510T1 (de) 1985-08-08 1986-08-07 Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.

Country Status (6)

Country Link
US (1) US4690915A (de)
EP (1) EP0211769B1 (de)
JP (1) JPS62116518A (de)
AT (1) ATE74510T1 (de)
CA (1) CA1297002C (de)
DE (1) DE3684732D1 (de)

Families Citing this family (503)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5192537A (en) * 1984-03-30 1993-03-09 Cellcor Inc. Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4883662A (en) * 1984-04-10 1989-11-28 Clinical Biotechnologies, Inc. Method of increasing natural killer cell population of cancer patients
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5308626A (en) * 1985-06-28 1994-05-03 Toni N. Mariani Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases
US4902288A (en) * 1985-12-03 1990-02-20 Marylou Ingram Implantable immunotherapy system using stimulated cells
EP0302894B1 (de) * 1986-04-28 1992-11-19 Endotronics Inc. Zuchtverfahren für leukocyten
US5002879A (en) * 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
US4829002A (en) * 1986-05-12 1989-05-09 Baxter International Inc. System for metering nutrient media to cell culture containers and method
US4937194A (en) * 1986-05-12 1990-06-26 Baxter International Inc. Method for metering nutrient media to cell culture containers
US4971795A (en) * 1986-07-08 1990-11-20 Biomira, Inc. Enhancement of the cellular immune response using carbohydrate primed DTH effector cells expressing the CD5+/CD8- phenotype
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
ATE107861T1 (de) * 1986-09-19 1994-07-15 Oncogen Verwendung von aktivierten t-lymphozyten zur vorbereitung einer pharmazeutischen zusammensetzung zur behandlung von aids.
US4861589A (en) * 1987-03-23 1989-08-29 Trustees Of Boston University Method for therapeutically treating abnormal cells expressing a major histocompatibility complex class II antigen using cytolytic inducer T4 cells
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
JPH02501534A (ja) * 1987-09-22 1990-05-31 バンデンバーク・アーサー・アレン 細胞表面決定基の発現および機能を選択的に調節する方法およびこれによりつくられる新規な人間細胞の産生
US5041289A (en) * 1987-11-13 1991-08-20 Becton Dickinson And Company Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
US5057423A (en) * 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
US5066489A (en) * 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
CA1329119C (en) * 1988-03-29 1994-05-03 Milton David Goldenberg Cytotoxic therapy
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US20030232010A2 (en) * 1988-03-29 2003-12-18 Immunomedics, Inc. Improved cytotoxic therapy
US5278143A (en) * 1988-04-25 1994-01-11 Trustees Of Boston University Prophylactic and therapeutic methods for treating interleukin-mediated edemas
FR2635527B1 (fr) * 1988-07-28 1992-06-12 Roussel Uclaf Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
GB8826298D0 (en) * 1988-11-10 1988-12-14 Williams N S Production of lak cells compositions containing them & their use in cancer therapy
US6143508A (en) * 1989-06-29 2000-11-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Device and process for cell capture and recovery
CA1340565C (en) * 1989-06-29 1999-05-25 Thomas B. Okarma Device and process for cell capture and recovery
US5108760A (en) * 1989-07-21 1992-04-28 Terumo Corporation Enhances lak cell activation by treatment of human peripheral blood mononuclear cells with amino acid amides
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
CA2066645A1 (en) * 1989-09-14 1991-03-15 Richard A. Knazek Method for the production of in vitro expanded lymphoid cells for use in adoptive immunotherapy
JPH0728732B2 (ja) * 1990-04-17 1995-04-05 日本石油株式会社 動物細胞増殖促進剤及び無血清培地
US5344755A (en) * 1990-04-21 1994-09-06 The United States Of America As Represented By The Department Of Health And Human Services Method for detecting immune system dysfunction in asymptomatic, HIV-scropositive individuals
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
DK0567586T3 (da) * 1991-01-16 1995-12-04 Schering Corp Anvendelse af interleukin-10 ved adoptiv immunterapi af cancer
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US5843728A (en) * 1991-03-07 1998-12-01 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) * 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US5725855A (en) * 1991-04-05 1998-03-10 The United States Of America As Represented By The Department Of Health And Human Services Method of treating tumors with CD8+ -depleted or CD4+ T cell subpopulations
EP0578740A4 (en) * 1991-04-05 1995-12-20 Univ Minnesota Method of enhancing the immunotherapeutic activity of immune cells by depletion/positive selection of cell subsets
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
IE922233A1 (en) * 1991-07-10 1993-01-13 Augusto C Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase¹their in vivo activity
WO1993003770A1 (en) * 1991-08-23 1993-03-04 Board Of Regents Of The University Of Nebraska Method and compositions for cellular reprogramming
EP0624095B2 (de) * 1991-12-31 2005-07-20 Zymogenetics, Inc. Verfahren und zusammensetzungen zur verminderung von blutverlust
US5296353A (en) * 1992-04-06 1994-03-22 The United States Of America As Represented By The Department Of Health And Human Services Evaluation and treatment of patients with progessive immunosuppression
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
US5229109A (en) * 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
WO2003040165A2 (en) 2000-10-19 2003-05-15 Epimmune Inc. Hla class i and ii binding peptides and their uses
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
US5670352A (en) * 1993-03-18 1997-09-23 Behringwerke Aktiengesellschaft Stable growth transformation of human T-lymphocytes by Herpesvirus saimiri (H. saimiri) subgroup C
EP0702563B1 (de) * 1993-05-27 2003-08-06 EntreMed, Inc. Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
US5536642A (en) * 1993-09-09 1996-07-16 Barbera-Guillem; Emilio Diagnostic and prognostic methods for solid non-lymphoid tumors and their metastases
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5997873A (en) 1994-01-13 1999-12-07 Mount Sinai School Of Medicine Of The City University Of New York Method of preparation of heat shock protein 70-peptide complexes
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
IL112969A (en) * 1994-03-17 2001-05-20 Baxter Int Pharmaceutical compositions for the treatment of cancer comprising allogenic lymphocytes or their combination with a t-cell activator
US5709995A (en) * 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
EP0775197A1 (de) * 1994-08-08 1997-05-28 Maxim Pharmaceuticals, Inc. Verstärkte aktivierung von natürlicher killerzellen durch verwendung von einem fängern oder hemmern des wasserstoffperoxids
US6045802A (en) * 1994-10-03 2000-04-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule
ATE197765T1 (de) 1994-10-03 2000-12-15 Us Gov Health & Human Serv Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US5935847A (en) * 1994-10-28 1999-08-10 Baxter International Inc. Multilayer gas-permeable container for the culture of adherent and non-adherent cells
US6297046B1 (en) 1994-10-28 2001-10-02 Baxter International Inc. Multilayer gas-permeable container for the culture of adherent and non-adherent cells
US7361332B2 (en) 1995-03-17 2008-04-22 The Regents Of The University Of California Treating tumors using implants comprising combinations of allogeneic cells
US6391404B1 (en) 1995-06-07 2002-05-21 Baxter International Inc. Coextruded multilayer film materials and containers made therefrom
US6024220A (en) * 1995-06-07 2000-02-15 Baxter International Inc. Encapsulated seam for multilayer materials
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5627070A (en) * 1995-07-26 1997-05-06 Celltherapy, Inc. Cell growing device for in vitro cell population expansion
US5837251A (en) * 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
US6805861B2 (en) 1996-01-17 2004-10-19 Imperial College Innovations Limited Immunotherapy using cytotoxic T lymphocytes (CTL)
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
US6130087A (en) * 1996-10-07 2000-10-10 Fordham University Methods for generating cytotoxic T cells in vitro
US5830464A (en) 1997-02-07 1998-11-03 Fordham University Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
US6017540A (en) * 1997-02-07 2000-01-25 Fordham University Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
US5981472A (en) * 1997-02-21 1999-11-09 Dx/Ibr Corporation Methods for treating diseases
US6884414B1 (en) * 1997-04-30 2005-04-26 Mount Sinai School Of Medicine Of New York University Recombinant influenza viruses expressing tumor-associated antigens as antitumor agents
US6872518B2 (en) 1997-09-22 2005-03-29 University Of Rochester Methods for selecting polynucleotides encoding T cell epitopes
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US5948646A (en) 1997-12-11 1999-09-07 Fordham University Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
ES2355483T3 (es) * 1998-02-20 2011-03-28 University Of Miami Complejo de proteina de choque térmico modificada-péptido antigénico.
DK1060247T3 (da) 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
US6790604B1 (en) 1998-05-12 2004-09-14 Stefan A. Cohen Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells
ES2326146T3 (es) 1998-06-17 2009-10-01 Idm Pharma, Inc. Peptidos de union a hla y sus usos.
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
US6929791B2 (en) 1998-07-16 2005-08-16 Institut Pasteur Peptides of IL-2 and derivatives thereof
US20020092987A1 (en) * 1998-09-05 2002-07-18 Taehee Cho Photo detect device using quantum dots and materialization method thereof
US6451316B1 (en) 1998-10-05 2002-09-17 University Of Conneticut Health Center Methods for generating antigen-reactive T cells in vitro
DE69942100D1 (de) 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6787154B2 (en) * 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
US7807377B2 (en) 1998-10-20 2010-10-05 Salvatore Albani Method of isolating antigen-specific T cells employing artificial antigen presenting cells
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US20040266834A1 (en) * 1999-10-14 2004-12-30 Copland John A. Thiazolidinediones alone or in cabination with other therapeutic agents for cancer therapy
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
US20030194696A1 (en) * 2000-03-28 2003-10-16 University Of Rochester Methods of producing a library and methods of selecting polynucleotides of interest
JP2003528605A (ja) * 2000-03-28 2003-09-30 ユニヴァーシティー オヴ ロチェスター ライブラリーを作成する方法および目的のポリヌクレオチドを選択する方法
US7449557B2 (en) 2000-06-02 2008-11-11 University Of Connecticut Health Center Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
CZ2003214A3 (cs) 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
ES2282148T3 (es) * 2000-11-30 2007-10-16 Imperial Innovations Limited Metodos y moleculas inmunoterapeuticos.
EP1356048A2 (de) 2000-12-04 2003-10-29 Argonex Pharmaceuticals Zytotoxisch t-lymphozyte induzierende immunogene zur krebsvorbeugung,behandlung, und diagnose
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6855925B2 (en) * 2001-02-14 2005-02-15 Picoliter Inc. Methods, devices, and systems using acoustic ejection for depositing fluid droplets on a sample surface for analysis
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
BR0209177A (pt) 2001-05-03 2004-10-05 Merck Patent Gmbh Anticorpo especìfico a tumor recombinante e uso do mesmo
HK1079705A1 (zh) * 2001-08-20 2006-04-13 University Of Connecticut Health Center 包含用於治疗癌症及感染性疾病的热休克蛋白或α2-巨球蛋白的组合物制备方法
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
AU2002341717A1 (en) * 2001-09-17 2003-04-01 Medcell Biologics, Llc. Cell therapy system
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
RU2201762C1 (ru) * 2001-10-09 2003-04-10 Свадовский Александр Игоревич Способ лечения внутримозговой опухоли головного мозга
CN1628167A (zh) * 2001-11-22 2005-06-15 医学基因公司 白细胞介素-2基因转移的淋巴因子活化的杀伤细胞
EP1454138B1 (de) 2001-12-04 2012-01-18 Merck Patent GmbH Immunocytokine mit modulierter selektivität
US20040236514A1 (en) * 2001-12-13 2004-11-25 Lee Stephen C. Controlling distribution of epitopes in polypeptide sequences
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
AU2003274463B2 (en) 2002-06-10 2009-10-29 University Of Rochester Gene differentially expressed in breast and bladder cancer and encoded polypeptides
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US9809654B2 (en) * 2002-09-27 2017-11-07 Vaccinex, Inc. Targeted CD1d molecules
ATE471946T1 (de) 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
JP2006514088A (ja) * 2003-02-20 2006-04-27 ユニバーシティー オブ コネティカット ヘルス センター 癌および感染症の治療における熱ショックタンパク質またはα−2−マクログロブリンを含む組成物の使用方法
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
US20040242676A1 (en) * 2003-05-30 2004-12-02 Alessi Thomas R. Method of mitigating the adverse effects of IL-2
WO2005044982A2 (en) 2003-09-05 2005-05-19 Oregon Health & Science University Monomeric recombinant mhc molecules useful for manipulation of antigen-specific t cells
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
JP5060134B2 (ja) 2003-12-12 2012-10-31 ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ ヒト細胞傷害性Tリンパ球のエピトープ及びそのMUC−1の非VNTR(non−variablenumberoftandemrepeatsequence)由来のアゴニストエピトープ
US7838503B2 (en) * 2005-06-15 2010-11-23 Children's Medical Center Corporation Methods for extending the replicative lifespan of cells
EP1937307A4 (de) * 2005-09-14 2009-05-13 Hutchinson Fred Cancer Res Spezifische entfernung von aktivierten immunzellen
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
AU2007281934B2 (en) 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
CA2643337C (en) * 2006-03-01 2016-01-12 Janssen Pharmaceutica N.V. Cancer treatment combining lymphodepleting agent with ctls and cytokines
US20080107668A1 (en) * 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039969A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP2112930B1 (de) * 2007-02-21 2017-01-11 Vaccinex, Inc. Modulation der nkt-zellaktivität mit antigenbeladenen cdid-molekülen
EP2155241A4 (de) * 2007-05-04 2010-06-02 Boris Skurkovich Verhinderung von krebs durch immunisierung
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
KR20100072228A (ko) 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
US9090875B2 (en) 2008-01-29 2015-07-28 Fred Hutchinson Cancer Research Center Identifcation of CD8+ T cells that are CD161hi and/or IL18Rαhi and have rapid drug efflux capacity
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2009226077B2 (en) 2008-03-20 2012-04-19 University Of Miami Heat shock protein gp96 vaccination and methods of using same
WO2009139921A2 (en) * 2008-05-16 2009-11-19 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
US8758765B2 (en) * 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US20110262477A1 (en) 2008-10-06 2011-10-27 University Of Chicago Compositions and Methods Related to Bacterial EAP, EMP, and/or ADSA Proteins
EP2358383A4 (de) * 2008-11-21 2011-11-23 Univ Miami Hiv/siv-impfstoffe zur herstellung von schleimhaut- und systemimmunität
KR101928684B1 (ko) 2009-01-08 2018-12-12 앨버트 아인슈타인 컬리지 오브 메디신, 인크. 세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
HRP20160274T1 (hr) 2009-04-03 2016-04-08 University Of Chicago Pripravci i metode vezane za varijante proteina a (spa)
PL2427485T3 (pl) 2009-05-07 2017-10-31 Immunocellular Therapeutics Ltd Epitopy CD133
WO2011025572A1 (en) 2009-08-26 2011-03-03 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US8075895B2 (en) 2009-09-22 2011-12-13 Janssen Pharmaceutica N.V. Identification of antigenic peptides from multiple myeloma cells
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
EP2555794A4 (de) 2010-04-05 2014-01-15 Univ Chicago Zusammensetzungen und verfahren im zusammenhang mit protein-a-(spa)-antikörpern als immunreaktionsverstärker
US9115402B2 (en) 2010-05-14 2015-08-25 Dana-Farber Cancer Institute, Inc. Compositions and methods of identifying tumor specific neoantigens
AU2011274367B2 (en) 2010-07-02 2015-04-23 The University Of Chicago Compositions and methods related to protein A (SpA) variants
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 感染防御ブドウ球菌抗原が関与する方法および組成物
CA2816379A1 (en) 2010-10-27 2012-05-03 Baylor College Of Medicine Chimeric cd27 receptors for redirecting t cells to cd70-positive malignancies
WO2012129514A1 (en) 2011-03-23 2012-09-27 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP2505640A1 (de) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
BR112013032421A2 (pt) 2011-06-29 2017-01-17 Immunotope Inc método para profilaxia ou tratamento de uma infecção pelo vírus da dengue, método para induzir uma resposta imune mediada por linfócito t citotóxico, vacina contra o vírus da dengue, método para prevenir uma doença causada pelo vírus da dengue e método para induzir uma resposta imune a pelo menos um vírus da dengue
US9624284B2 (en) 2011-09-13 2017-04-18 Immunotope, Inc. Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer
EP3692794A1 (de) 2011-09-16 2020-08-12 Baylor College of Medicine Gegen die tumormikroumgebung gerichtete manipulierte nkt-zellen
EP2760995B1 (de) 2011-09-30 2019-08-07 The University Of Miami Aus der niere isolierte nierenstammzellen
WO2013162746A1 (en) 2012-04-26 2013-10-31 University Of Chicago Staphylococcal coagulase antigens and methods of their use
EP2934532B1 (de) 2012-12-20 2019-10-23 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
US9371352B2 (en) 2013-02-08 2016-06-21 Vaccinex, Inc. Modified glycolipids and methods of making and using the same
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
AU2014251207B2 (en) 2013-04-07 2019-06-13 Dana-Farber Cancer Institute, Inc. Compositions and methods for personalized neoplasia vaccines
EP2997134B1 (de) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Menschliche anwendung manipulierter chimärer antigen-rezeptor (car)-t-zellen
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
WO2015130488A2 (en) 2014-02-28 2015-09-03 Immunotope, Inc. Mhc class i associated peptides for prevention and treatment of hepatitis b virus infection
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
US20170158749A1 (en) 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
KR20160145186A (ko) 2014-04-24 2016-12-19 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 입양 세포 요법 생성물을 생성하기 위한 유도 만능 줄기 세포의 응용
EP3805371A1 (de) 2014-05-15 2021-04-14 National University of Singapore Modifizierte natürliche killerzellen und verwendungen davon
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI751102B (zh) 2014-08-28 2022-01-01 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
BR112017008042A2 (pt) 2014-10-20 2017-12-26 Juno Therapeutics Inc métodos e composições para dosagem em terapia de célula adotiva
JP6740234B2 (ja) 2014-11-05 2020-08-12 ジュノー セラピューティクス インコーポレイテッド 形質導入および細胞プロセシングのための方法
CA2964783C (en) 2014-11-05 2024-01-23 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) to selectively target protein complexes
CA2964785A1 (en) 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
EP3227323B1 (de) 2014-12-03 2020-08-05 Juno Therapeutics, Inc. Verfahren und zusammensetzungen zur adoptiven zelltherapie
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
US20160208018A1 (en) 2015-01-16 2016-07-21 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for ror1
US10046047B2 (en) 2015-02-06 2018-08-14 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
JP6775515B2 (ja) 2015-03-11 2020-10-28 ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム トランスポザーゼポリペプチド及びその使用
WO2016154585A1 (en) 2015-03-26 2016-09-29 Charles Sentman Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
EP3294324A1 (de) 2015-05-13 2018-03-21 Agenus Inc. Impfstoffe zur behandlung und prävention von krebs
JP6913032B2 (ja) 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
TW202241500A (zh) 2015-06-09 2022-11-01 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
KR20180043800A (ko) 2015-09-09 2018-04-30 이뮨 디자인 코포레이션 Ny-eso-1 특이적 tcrs 및 그의 사용 방법
EP3350212A1 (de) 2015-09-18 2018-07-25 INSERM - Institut National de la Santé et de la Recherche Médicale T-zell-rezeptoren (tcr) und verwendungen davon zur diagnose und behandlung von diabetes
ES2768957T3 (es) 2015-09-24 2020-06-24 Abvitro Llc Composiciones de anticuerpos contra el VIH y métodos de uso
AU2016326734B2 (en) 2015-09-25 2022-07-07 Abvitro Llc High throughput process for T cell receptor target identification of natively-paired T cell receptor sequences
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
WO2017055273A1 (en) 2015-09-28 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Biofunctionalized nanoparticles and uses thereof in adoptive cell therapy
WO2017055319A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of b cells in a tissue sample
WO2017055320A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cytotoxic lymphocytes in a tissue sample
WO2017055324A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of cells of monocytic origin in a tissue sample
WO2017055327A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of endothelial cells in a tissue sample
WO2017055325A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of nk cells in a tissue sample
WO2017055321A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of fibroblasts in a tissue sample
WO2017055322A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of neutrophils in a tissue sample
WO2017055326A1 (en) 2015-09-29 2017-04-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
RU2761555C2 (ru) 2015-10-22 2021-12-09 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
WO2017075147A1 (en) 2015-10-27 2017-05-04 Board Of Regents, The University Of Texas System Chimeric antigen receptor molecules and uses thereof
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
MX2018006789A (es) 2015-12-03 2019-02-13 Juno Therapeutics Inc Receptores quimericos modificados y composiciones y metodos relacionados.
US20200297760A1 (en) 2015-12-03 2020-09-24 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against chimeric antigen receptors
WO2017096331A1 (en) 2015-12-04 2017-06-08 Juno Therapeutics, Inc. Methods and compositions related to toxicity associated with cell therapy
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
WO2017161208A1 (en) 2016-03-16 2017-09-21 Juno Therapeutics, Inc. Methods for determining dosing of a therapeutic agent and related treatments
CN109476743A (zh) 2016-03-22 2019-03-15 西雅图儿童医院(以西雅图儿童研究所名义营业) 预防或缓解毒性的早期干预方法
CA3019835A1 (en) 2016-04-08 2017-10-12 Purdue Research Foundation Methods and compositions for car t cell therapy
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3452499A2 (de) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Gentechnisch veränderte zellen und verfahren zur herstellung davon
WO2017210689A1 (en) 2016-06-03 2017-12-07 Memorial Sloan-Kettering Cancer Center Adoptive cell therapies as early treatment options
WO2017214207A2 (en) 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
JP7054397B2 (ja) 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Mhc-e拘束性エピトープ、結合分子ならびに関連する方法および使用
WO2018011166A2 (en) 2016-07-12 2018-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for quantifying the population of myeloid dendritic cells in a tissue sample
EP3269739A1 (de) 2016-07-15 2018-01-17 OGD2 Pharma Humanisierter antikörper gegen o-acetyliertes gd2-gangliosid (oacgd2)
EP3491022B1 (de) 2016-07-29 2025-09-10 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper gegen tumor-assoziierte makrophagen und verwendungen davon
JP7295795B2 (ja) 2016-07-29 2023-06-21 ジュノー セラピューティクス インコーポレイテッド 免疫調節ポリペプチドならびに関連する組成物および方法
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
KR20190062505A (ko) 2016-10-03 2019-06-05 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
EP3525803B1 (de) 2016-10-13 2022-12-07 Juno Therapeutics, Inc. Immuntherapieverfahren und zusammensetzungen mit tryptophan-stoffwechselweg-modulatoren
CA3042049A1 (en) 2016-11-03 2018-05-11 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and a btk inhibitor
MA46716A (fr) 2016-11-03 2019-09-11 Juno Therapeutics Inc Polythérapie de thérapie cellulaire et d'inhibiteur de la microglie
WO2018102612A1 (en) 2016-12-02 2018-06-07 Juno Therapeutics, Inc. Engineered b cells and related compositions and methods
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
US20200078400A1 (en) 2016-12-03 2020-03-12 Juno Therapeutics, Inc. Methods for determining car-t cells dosing
JP2019536460A (ja) 2016-12-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Car−t細胞の調節方法
WO2018106732A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
EP3571221A2 (de) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Zelloberflächenkonjugate und verwandte zellzusammensetzungen und verfahren
EP3574116A1 (de) 2017-01-24 2019-12-04 The Broad Institute, Inc. Zusammensetzungen und verfahren zum nachweis einer mutanten variante eines polynukleotids
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
IL268349B2 (en) 2017-02-17 2024-08-01 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
US11274160B2 (en) 2017-03-02 2022-03-15 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to Nectin-4 and uses thereof
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
CN110913954A (zh) 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
EP3595705A1 (de) 2017-03-15 2020-01-22 Oxford BioMedica (UK) Limited Verfahren
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
WO2018187260A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3385373A1 (de) 2017-04-05 2018-10-10 Centro de Neurociências e Biologia Celular Zusammensetzungen zur umprogrammierung von zellen in dendritischen zellen oder antigen-präsentierende zellen, verfahren und verwendungen davon
US11345891B2 (en) 2017-04-05 2022-05-31 Asgard Therapeutics Ab Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof
MX2019012017A (es) 2017-04-07 2020-02-12 Juno Therapeutics Inc Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
AU2018260380B2 (en) 2017-04-27 2025-02-13 Juno Therapeutics Gmbh Oligomeric particle reagents and methods of use thereof
PL3618842T3 (pl) 2017-05-01 2024-02-19 Juno Therapeutics, Inc. Kombinacja terapii komórkowej i związku immunomodulującego
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
IL327498A (en) 2017-06-02 2026-05-01 Juno Therapeutics Inc Articles of manufacture and methods for treatment using adoptive cell therapy
EP3631468A1 (de) 2017-06-02 2020-04-08 Juno Therapeutics, Inc. Artikel zur herstellung und verfahren im zusammenhang mit der mit einer zelltherapie einherenden toxizität
CN110997902B (zh) 2017-06-20 2021-11-30 居里研究所 Suv39h1缺陷的免疫细胞
IL299348B2 (en) 2017-06-28 2025-05-01 Regeneron Pharma Antigen-binding proteins against human papillomavirus and methods of using them
KR20200030593A (ko) 2017-07-21 2020-03-20 버클리 라잇츠, 인크. 항원 제시 합성 표면, 공유결합으로 관능화된 표면, 활성화된 t 세포, 및 이들의 용도
EP4516896A3 (de) 2017-08-09 2025-05-14 Juno Therapeutics, Inc. Verfahren und zusammensetzungen zur herstellung genetisch manipulierter zellen
KR102755437B1 (ko) 2017-08-09 2025-01-20 주노 쎄러퓨티크스 인코퍼레이티드 유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
WO2019054865A1 (en) 2017-09-14 2019-03-21 ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) T-cell based immunotherapy
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3081456A1 (en) 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
JP7357626B2 (ja) 2017-11-01 2023-10-06 ジュノー セラピューティクス インコーポレイテッド 操作された細胞の治療用組成物を生成するためのプロセス
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
CA3080509A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Process for producing a t cell composition
MA49911A (fr) 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
JP2021502077A (ja) 2017-11-06 2021-01-28 エディタス・メディシン,インコーポレイテッド 免疫療法のためのt細胞におけるcblbのcrispr−cas9編集のための方法、組成物および構成要素
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11618884B2 (en) 2017-11-14 2023-04-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Regulatory T cells genetically modified for the lymphotoxin alpha gene and uses thereof
MA51210A (fr) 2017-12-01 2020-10-07 Juno Therapeutics Inc Procédés de dosage et de modulation de cellules génétiquement modifiées
BR112020011223A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc marcadores fenotípicos para terapia celular e mé-todos relacionados
AU2018379091A1 (en) 2017-12-08 2020-06-25 Juno Therapeutics, Inc. Serum-free media formulation for culturing cells and methods of use thereof
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
EP3724225A1 (de) 2017-12-15 2020-10-21 Juno Therapeutics, Inc. Anti-cct5-bindende moleküle und verfahren zur verwendung davon
KR102327512B1 (ko) 2018-01-12 2021-11-17 주식회사 큐로셀 이원 shrna를 이용한 향상된 면역 세포 및 이를 포함하는 조성물
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
CN111971059A (zh) 2018-01-31 2020-11-20 细胞基因公司 使用过继细胞疗法和检查点抑制剂的组合疗法
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
DE102018108996B4 (de) 2018-02-09 2021-10-21 Immatics US, Inc. Verfahren zur Herstellung autologer T-Zellen
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
SG11202008008UA (en) 2018-02-21 2020-09-29 Univ Texas Universal antigen presenting cells and uses thereof
JP7568224B2 (ja) 2018-02-23 2024-10-16 エンドサイト・インコーポレイテッド Car t細胞療法のための配列決定法
WO2019170845A1 (en) 2018-03-09 2019-09-12 Ospedale San Raffaele S.R.L. Il-1 antagonist and toxicity induced by cell therapy
EP3765053A2 (de) 2018-03-16 2021-01-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigene peptide aus urocortin 3 und verwendungen davon zur diagnose und behandlung von typ-1-diabetes
US20210023209A1 (en) 2018-03-16 2021-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019175380A2 (en) 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
WO2019183500A1 (en) 2018-03-23 2019-09-26 Hung Chiung Yu Coccidioides antigens and methods of their use
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
EP3784688A2 (de) 2018-04-26 2021-03-03 Agenus Inc. Hitzeschockproteinbindende peptidzusammensetzungen und verfahren zu deren verwendung
BR112020022185A2 (pt) 2018-05-03 2021-02-02 Juno Therapeutics Inc terapia de combinação de uma terapia de células t do receptor de antígeno quimérico (car) e um inibidor de quinase
JP2021524233A (ja) 2018-05-17 2021-09-13 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 薬物耐性免疫細胞及びその用途
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
BR112021002390A2 (pt) 2018-08-09 2021-05-11 Juno Therapeutics Inc processos para gerar células modificadas e suas composições
CN112805378A (zh) 2018-08-09 2021-05-14 朱诺治疗学股份有限公司 用于评估整合核酸的方法
CA3110089A1 (en) 2018-08-28 2020-03-05 Fred Hutchinson Cancer Research Center Methods and compositions for adoptive t cell therapy incorporating induced notch signaling
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
BR112021003757A2 (pt) 2018-08-31 2021-05-25 Invectys SA receptores de antígenos quiméricos contra múltiplas isoformas de hla-g
WO2020053122A1 (en) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of her2/neu antibody with heme for treating cancer
US12239699B2 (en) 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
KR20210063362A (ko) 2018-09-21 2021-06-01 버클리 라잇츠, 인크. 작용화된 웰 플레이트, 이의 제조 및 사용 방법
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
WO2020081875A1 (en) 2018-10-18 2020-04-23 Berkeley Lights, Inc. Proto-antigen-presenting synthetic surfaces, activated t cells, and uses thereof
CN113454110B (zh) 2018-10-23 2024-07-02 里珍纳龙药品有限公司 Ny-eso-1 t细胞受体和其使用方法
WO2020089343A1 (en) 2018-10-31 2020-05-07 Juno Therapeutics Gmbh Methods for selection and stimulation of cells and apparatus for same
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
CN119569895A (zh) 2018-11-01 2025-03-07 朱诺治疗学股份有限公司 G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体
US20210393691A1 (en) 2018-11-06 2021-12-23 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
CN113573719A (zh) 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 治疗和t细胞调节的方法和组合
BR112021009420A2 (pt) 2018-11-16 2021-11-23 Juno Therapeutics Inc Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
EP4427810A3 (de) 2018-11-30 2024-12-04 Juno Therapeutics, Inc. Behandlungsverfahren mit adoptiver zelltherapie
KR20210110811A (ko) 2018-11-30 2021-09-09 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법에서 b 세포 악성 종양의 투약 및 치료 방법
WO2020123716A1 (en) 2018-12-11 2020-06-18 Obsidian Therapeutics, Inc. Membrane bound il12 compositions and methods for tunable regulation
WO2020120649A1 (en) 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020148207A1 (en) 2019-01-14 2020-07-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies binding to hla-a2
WO2020150832A1 (en) 2019-01-24 2020-07-30 Valorisation-Hsj, Limited Partnership Cell-specific transcriptional regulatory sequences and uses thereof
EA202192103A1 (ru) 2019-01-29 2021-12-15 Джуно Терапьютикс, Инк. Антитела и химерные антигенные рецепторы, специфичные к орфанному рецептору типа рецеторной тирозинкиназы 1 (ror1)
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
CN113811329B (zh) 2019-04-19 2025-10-14 天科雅生物科技有限公司 抗pd-1抗体和其用途
SG11202111372VA (en) 2019-05-01 2021-11-29 Juno Therapeutics Inc Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
CA3136737A1 (en) 2019-05-01 2020-11-05 Juno Therapeutics, Inc. Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
JP2022533591A (ja) 2019-05-14 2022-07-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル リンホトキシンアルファ遮断剤によりターゲットされた制御性t細胞及びその使用
CA3139981A1 (en) 2019-05-14 2020-11-19 The University Of Chicago Methods and compositions comprising staphylococcus protein a (spa) variants
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
EP3994245A1 (de) 2019-07-05 2022-05-11 Case Western Reserve University Priming-medium und verfahren für stammzellenkultur und -therapie
WO2021009263A1 (en) 2019-07-16 2021-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for cd38 and uses thereof
EP4003407A1 (de) 2019-07-23 2022-06-01 Mnemo Therapeutics Suv39h1-deffiziente immunzellen
BR112022001194A2 (pt) 2019-07-24 2022-06-07 Regeneron Pharma Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
KR20220066892A (ko) 2019-08-22 2022-05-24 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 제스트 동족체 2의 인핸서 (ezh2) 억제제의 병용 요법 및 관련 방법
US20230092895A1 (en) 2019-08-30 2023-03-23 Obsidian Therapeutics, Inc. Tandem cd19 car-based compositions and methods for immunotherapy
CN114651003A (zh) 2019-09-10 2022-06-21 黑曜石疗法公司 用于可调调节的ca2-il15融合蛋白
US12528882B2 (en) 2019-09-13 2026-01-20 The University Of Chicago Methods and compositions for treating staphylococcal infections
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US20240083973A1 (en) 2019-10-09 2024-03-14 Ecole Normale Supérieure de Lyon T cells modified to express mutated cxcr4 or partially deleted and uses thereof
EP4045663A2 (de) 2019-10-16 2022-08-24 Umoja Biopharma, Inc. Retroviraler vektor zur universellen rezeptortherapie
MX2022005145A (es) 2019-10-30 2022-06-29 Juno Therapeutics Gmbh Dispositivos de estimulación y/o selección celular y método de uso.
CN120605327A (zh) 2019-11-06 2025-09-09 贝勒医学院 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法
EP4054623A1 (de) 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Kombination aus einer t-zelltherapie und (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]-piperidin-2,6-dion
WO2021105234A1 (en) 2019-11-25 2021-06-03 Asgard Therapeutics Ab Compositions for reprogramming cells into dendritic cells type 2 competent for antigen presentation, methods and uses thereof
EP4070097A1 (de) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Verfahren in zusammenhang mit toxizität und ansprechen bei einer zelltherapie zur behandlung von b-zell-malignitäten
EP4072682A1 (de) 2019-12-09 2022-10-19 Institut National de la Santé et de la Recherche Médicale (INSERM) Antikörper mit spezifität gegen her4 und verwendungen davon
AU2021205416B2 (en) 2020-01-08 2026-08-06 Obsidian Therapeutics, Inc. Compositions and methods for tunable regulation of transcription
US20230071910A1 (en) 2020-01-24 2023-03-09 Juno Therapeutics, Inc. Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy
BR112022014461A2 (pt) 2020-01-24 2022-09-13 Regeneron Pharma Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos
US20230090117A1 (en) 2020-01-28 2023-03-23 Juno Therapeutics, Inc. Methods for t cell transduction
JP2023519099A (ja) 2020-02-12 2023-05-10 ジュノー セラピューティクス インコーポレイテッド Bcma指向性キメラ抗原受容体t細胞組成物ならびにその方法および使用
EP4110823A1 (de) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
US12091681B2 (en) 2020-03-27 2024-09-17 Mendus B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CA3172447A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
IL297147B1 (en) 2020-04-10 2026-05-01 Juno Therapeutics Inc Methods and uses related to engineered cell therapy with a chimeric antigen receptor directed against a B-cell maturation antigen
CA3181399A1 (en) 2020-04-28 2021-11-04 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
WO2021226063A1 (en) 2020-05-05 2021-11-11 Regeneron Pharmaceuticals, Inc. Car comprising cd28 zeta and cd3 zeta
EP4149558A1 (de) 2020-05-12 2023-03-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
KR20230022868A (ko) 2020-05-13 2023-02-16 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
AU2021278356A1 (en) 2020-05-27 2022-11-03 Antion Biosciences Sa Adapter molecules to re-direct CAR T cells to an antigen of interest
WO2021257679A1 (en) 2020-06-17 2021-12-23 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells
EP4171616A1 (de) 2020-06-26 2023-05-03 Juno Therapeutics GmbH Manipulierte t-zellen zur bedingten expression eines rekombinanten rezeptors, zugehörige polynukleotide und verfahren
WO2022003568A1 (en) 2020-06-30 2022-01-06 Dcprime B.V. Use of leukemia-derived cells in ovarian cancer vaccines
CA3186065A1 (en) 2020-07-16 2022-01-20 Xiaohu FAN Cd19 binding molecules and uses thereof
US20230272039A1 (en) 2020-07-16 2023-08-31 Umoja Biopharma, Inc. Gated adapter targeting receptor
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Cd20結合分子及びその使用
CA3188656A1 (en) 2020-07-17 2022-01-20 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
JP7886313B2 (ja) 2020-07-30 2026-07-07 アンスティテュ・クリー Socs1に欠陥のある免疫細胞
EP4189071A1 (de) 2020-08-03 2023-06-07 Institut National de la Santé et de la Recherche Médicale (INSERM) Population von treg-zellen, die funktionell mit einer regulatorischen aktivität behaftet sind, und ihre verwendung zur adoptiven therapie
US11433100B2 (en) 2020-08-20 2022-09-06 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4058474B1 (de) 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von egfr-positiven karzinomen
EP4097486A4 (de) 2020-08-20 2023-09-06 A2 Biotherapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von ceacam-positivem krebs
WO2022040454A1 (en) 2020-08-20 2022-02-24 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2022036458A1 (en) 2020-08-21 2022-02-24 12343096 Canada Inc. Modular assembly receptors and uses thereof
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
EP4204546A1 (de) 2020-08-31 2023-07-05 City of Hope Neue zelllinien, verfahren zur herstellung natürlicher killerzellen und verwendungen davon
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
WO2022060806A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells
WO2022074098A1 (en) 2020-10-08 2022-04-14 Fundació Privada Institut D'investigació Oncològica De Vall Hebron Method for the identification of cancer neoantigens
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントcd3免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
US20220168407A1 (en) 2020-11-05 2022-06-02 Dcprime B.V. Use of tumor-independent antigens in immunotherapies
EP4251282A1 (de) 2020-11-27 2023-10-04 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur diagnose und überwachung von toxischer epidermaler nekrolyse
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
CA3207206A1 (en) 2021-02-01 2022-08-04 Lingfeng LIU Targeted protein degradation system and use thereof
IL304857A (en) 2021-02-16 2023-10-01 A2 Biotherapeutics Inc Preparations and methods for treating HER2 POSITIVE cancer
JP2024507958A (ja) 2021-02-26 2024-02-21 ナンジン レジェンド バイオテック カンパニー,リミテッド 外因的に導入されたサイトカインを発現する操作された免疫エフェクター細胞
KR20230165771A (ko) 2021-03-03 2023-12-05 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법 및 dgk 억제제의 조합
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
CN117858719A (zh) 2021-03-29 2024-04-09 朱诺治疗学股份有限公司 使用检查点抑制剂疗法和car t细胞疗法的组合进行给药和治疗的方法
IL307257A (en) 2021-03-29 2023-11-01 Juno Therapeutics Inc A combination of car cell therapy and an immunomodulatory compound for the treatment of lymphoma
JP2024512808A (ja) 2021-04-05 2024-03-19 ヤンセン バイオテツク,インコーポレーテツド Calr及びjak2t細胞受容体
CN118201618A (zh) 2021-04-16 2024-06-14 细胞基因公司 与bcma定向t细胞疗法的组合疗法
JP2024516308A (ja) 2021-05-04 2024-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Mage-a4特異性を有するキメラ抗原受容体及びその使用
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
US20250304915A1 (en) 2021-05-25 2025-10-02 Institut Curie Myeloid Cells Overexpressing BCL2
JP2024528077A (ja) 2021-07-30 2024-07-26 ▲い▼尊生物医薬(浙江)有限公司 汎用型t細胞およびその応用
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
WO2023081735A1 (en) 2021-11-03 2023-05-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
EP4433512A4 (de) 2021-11-19 2025-12-31 Univ Pennsylvania Manipuliertes pan-leukozytenantigen cd45 zur erleichterung der car-t-zelltherapie
JP2025501272A (ja) 2021-12-28 2025-01-17 ムネモ・セラピューティクス 不活性化されたsuv39h1及び改変tcrを有する免疫細胞
AU2023209589A1 (en) 2022-01-21 2024-08-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Modulation of suv39h1 expression by rnas
AU2023217968A1 (en) 2022-02-09 2024-09-26 Janssen Biotech, Inc. Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
WO2023156587A1 (en) 2022-02-18 2023-08-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
AU2023225954A1 (en) 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
IL314801A (en) 2022-02-22 2024-10-01 Juno Therapeutics Inc Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses
CN119156403A (zh) 2022-03-08 2024-12-17 阿伦蒂斯治疗股份公司 抗紧密连接蛋白-1抗体增加t细胞可用性的用途
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
EP4279085A1 (de) 2022-05-20 2023-11-22 Mnemo Therapeutics Zusammensetzungen und verfahren zum behandeln eines refraktären oder rezidivierenden krebses oder einer chronischen infektionskrankheit
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
WO2023237663A1 (en) 2022-06-09 2023-12-14 Institut National de la Santé et de la Recherche Médicale Use of the f359l missense irf4 variant for increasing the stability of regulatory t cells
JP2025521543A (ja) 2022-06-22 2025-07-10 ジュノー セラピューティクス インコーポレイテッド Cd19標的car t細胞のセカンドライン治療のための処置方法
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024019984A1 (en) 2022-07-18 2024-01-25 Cargo Therapeutics, Inc. Cytokine receptor switch polypeptides and uses thereof
CN119907674A (zh) 2022-07-22 2025-04-29 詹森生物科技公司 遗传指令向效应免疫细胞的增强转移
EP4565262A2 (de) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimäre antigenrezeptoren spezifisch für gprc5d und bcma
US20260061051A1 (en) 2022-08-26 2026-03-05 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
WO2024047110A1 (en) 2022-08-31 2024-03-07 Institut National de la Santé et de la Recherche Médicale Method to generate more efficient car-t cells
WO2024052318A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
EP4584291A1 (de) 2022-09-08 2025-07-16 Institut National de la Santé et de la Recherche Médicale Antikörper mit spezifität gegen ltbp2 und verwendungen davon
KR20250061756A (ko) 2022-09-08 2025-05-08 주노 쎄러퓨티크스 인코퍼레이티드 T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024074713A1 (en) 2022-10-07 2024-04-11 Institut National de la Santé et de la Recherche Médicale Method to generate improving car-t cells
WO2024091944A1 (en) 2022-10-25 2024-05-02 Cargo Therapeutics, Inc. Split receptor switch polypeptides and uses thereof
EP4608854A2 (de) 2022-10-27 2025-09-03 Cargo Therapeutics, Inc. Zusammensetzungen und verfahren für allogene immuntherapien
EP4608856A1 (de) 2022-10-27 2025-09-03 CARGO Therapeutics, Inc. Zusammensetzungen und verfahren für verbesserte immuntherapien
WO2024091669A1 (en) 2022-10-28 2024-05-02 Ginkgo Bioworks, Inc. Chimeric antigen receptors comprising an intracellular domain pair
US20260166082A1 (en) 2022-11-02 2026-06-18 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
WO2024123760A1 (en) 2022-12-05 2024-06-13 Cargo Therapeutics, Inc. Multiplex cell selection compositions and uses thereof
US20260207667A1 (en) 2022-12-13 2026-07-23 Juno Therapeutics, Inc. Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
WO2024168276A2 (en) 2023-02-09 2024-08-15 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
CN120957741A (zh) 2023-03-13 2025-11-14 宾夕法尼亚大学董事会 用于肿瘤治疗的car修饰剂的产生
WO2024206155A1 (en) 2023-03-24 2024-10-03 Cornell University Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
KR20250169631A (ko) 2023-04-18 2025-12-03 주노 쎄러퓨티크스 인코퍼레이티드 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정
EP4702132A1 (de) 2023-04-26 2026-03-04 Institut National de la Santé et de la Recherche Médicale Verfahren zur modulation der differenzierung und funktionen menschlicher dendritischer zellen
EP4720109A1 (de) 2023-05-25 2026-04-08 Regeneron Pharmaceuticals, Inc. T-zell-rezeptoren, die präsentierte hpv16-, mart1-, cmv-, ebv- oder influenza-peptide binden
WO2025029930A1 (en) 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
WO2025049972A1 (en) 2023-09-01 2025-03-06 Cargo Therapeutics, Inc. Compositions and methods for immunotherapies
EP4777540A1 (de) 2023-09-13 2026-07-22 Juno Therapeutics, Inc. Kombinationstherapien mit einer zelltherapie mit expression eines gprc5d-targeting-car sowie zugehörige verfahren und verwendungen
KR20260088542A (ko) 2023-10-06 2026-06-12 주노 쎄러퓨티크스 인코퍼레이티드 Gprc5d-표적화 car을 발현하는 세포 요법을 사용한 조합 요법 및 관련 방법 및 용도
WO2025085680A1 (en) 2023-10-17 2025-04-24 Cargo Therapeutics, Inc. Methods for manufacturing car t cells
WO2025082603A1 (en) 2023-10-18 2025-04-24 Institut Curie Engineered immune cells overexpressing cd74 molecule
WO2025090978A1 (en) 2023-10-26 2025-05-01 Cargo Therapeutics, Inc. Modified immune effector cells
WO2025120015A1 (en) 2023-12-06 2025-06-12 Institut National de la Santé et de la Recherche Médicale Cd5 targeting antibodies with depleting and t or b-cell activation effects
WO2025125363A1 (en) 2023-12-11 2025-06-19 Institut National de la Santé et de la Recherche Médicale Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions
IL328711A (en) 2023-12-13 2026-07-01 Umoja Biopharma Inc Myeloid cells derived from engineered induced stem cells and methods for differentiating and using them
WO2025147545A1 (en) 2024-01-03 2025-07-10 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids and related methods and uses
WO2025163107A1 (en) 2024-02-01 2025-08-07 Institut Gustave Roussy Immune cells defective for znf217 and uses thereof
WO2025184421A1 (en) 2024-02-28 2025-09-04 Juno Therapeutics, Inc. Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods
WO2025224297A1 (en) 2024-04-26 2025-10-30 Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to tgfbi and uses thereof
WO2025245381A1 (en) 2024-05-23 2025-11-27 The Trustrees Of Dartmouth College Methods and compositions for enhancing the persistence of car expressing tregs in the cns and other tissues
WO2025255030A1 (en) 2024-06-03 2025-12-11 Cornell University Interferon gamma responsive chimeric t cell costimulatory receptor
WO2026002973A1 (en) 2024-06-25 2026-01-02 Institut National de la Santé et de la Recherche Médicale Host immune cells engineered to overexpress a foxk1 polypeptide
WO2026035951A2 (en) 2024-08-07 2026-02-12 Legend Biotech Ireland Limited Cells overexpressing cd43 and methods of use thereof
WO2026055226A1 (en) 2024-09-03 2026-03-12 Legend Biotech Ireland Limited Cells overexpressing b3gnt2 and methods of use thereof
WO2026086785A1 (en) 2024-10-21 2026-04-30 Shenzhen Wondercel Biotechnology Limited Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c
WO2026136848A2 (en) 2024-12-20 2026-06-25 Juno Therapeutics, Inc. Cd70-targeted cars and engineered cells comprising same and related methods
WO2026136970A1 (en) 2024-12-20 2026-06-25 Cargo Therapeutics, Inc. Methods for manufacturing car t cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175036D1 (en) * 1980-10-02 1986-09-04 Hooper Trading Co Nv A t-cell growth factor, and a process of producing the same
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
JPH0751511B2 (ja) * 1982-03-15 1995-06-05 味の素株式会社 インターロイキン2を含有してなる癌治療剤
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4530787A (en) * 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
JPS61500790A (ja) * 1984-03-28 1986-04-24 シタス コ−ポレイシヨン 微生物的に製造されたインターロイキン―2を含有する組成物
JPS62263127A (ja) * 1986-05-06 1987-11-16 メレルダウフア−マス−テイカルズ インコ−ポレ−テツド 自己由来のlak細胞、インタ−ロイキン−2、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置

Also Published As

Publication number Publication date
JPS62116518A (ja) 1987-05-28
EP0211769A3 (en) 1989-03-29
US4690915A (en) 1987-09-01
EP0211769B1 (de) 1992-04-08
CA1297002C (en) 1992-03-10
EP0211769A2 (de) 1987-02-25
DE3684732D1 (de) 1992-05-14

Similar Documents

Publication Publication Date Title
DE3684732D1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
US4789658A (en) Immunoprophylactic and immunotherapeutic agents
US5573764A (en) Use of interleukin-12 to prevent graft versus host disease
Biron et al. Interferon induces natural killer cell blastogenesis in vivo
US5443983A (en) Method of culturing lymphocytes and method of treatment using such lymphocytes
CA2205405C (en) Method for treating secondary immunodeficiency
Merluzzi et al. Expansion of cyclophosphamide-resistant cytotoxic precursors in vitro and in vivo by purified human interleukin 2.
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
EP0231819A3 (en) Pharmaceutical agent for the treatment of myelogenous leukemia
Dawson et al. Lymphokine activated killing of fresh human leukaemias
Nakamura et al. Immunomodulation by isoprinosine: effects on in vitro immune functions of lymphocytes from humans with autoimmune diseases
Garaci et al. Enhanced immune response and antitumor immunity with combinations of biological response modifiers
Platsoucas et al. Immunomodulation of human leukocytes by staphylococcal enterotoxin A: augmentation of natural killer cells and induction of suppressor cells
Nagatani et al. A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2)
Kedar et al. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes
Marolda et al. A phase I study of recombinant interleukin 2 in melanoma patients. Toxicity and clinical effects
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
Grimm et al. The lymphokine-activated killer cell phenomenon: in vitro and in vivo studies
Merluzzi et al. Lysis of spontaneous murine breast tumors by human interleukin 2-stimulated syngeneic T-lymphocytes
AU7336687A (en) Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
Jacobs et al. Lymphokine activateed killer (LAK) cell-mediated lysis of murine glioma: trypsinchymotrypsin-sensitive glioma protein is responsible for tumor-selective recognition by LAK cells
Merluzzi et al. Expansion of Murine Cytotoxic Precursors In Vitro and In Vivo by Purified Interleukin-2
Igarashi et al. Induction of the differentiation of memory T killer cells with factors released from macrophage-like cell lines
Hirashima et al. Induction of an eosinophil chemotactic factor production from T lymphocytes by a B cell lymphoma line
Moltó et al. Thymostimulin enhances the natural cytotoxic activity of patients with transitional cell carcinoma of the bladder

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time